HIK.L - Hikma Pharmaceuticals PLC

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Show:
Balance sheet
Cash flow
Annual

Income statement

Currency in USD. All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
2,517,000
2,517,000
2,553,000
2,341,000
2,207,000
Cost of revenue
1,279,000
1,279,000
1,252,000
1,140,000
1,059,000
Gross profit
1,238,000
1,238,000
1,301,000
1,201,000
1,148,000
Operating expenses
Research development
144,000
144,000
143,000
137,000
150,000
Selling general and administrative
509,000
509,000
488,000
464,000
494,000
Total operating expenses
741,000
756,000
742,000
687,000
655,000
Operating income or loss
497,000
482,000
559,000
514,000
493,000
Interest expense
63,000
77,000
69,000
69,000
67,000
Income before tax
233,000
233,000
544,000
558,000
491,000
Income tax expense
42,000
42,000
124,000
128,000
4,000
Income from continuing operations
191,000
191,000
420,000
430,000
487,000
Net income
188,000
188,000
421,000
431,000
486,000
Net income available to common shareholders
188,000
188,000
421,000
431,000
486,000
Basic EPS
-
0.84
1.82
1.83
2.01
Diluted EPS
-
0.84
1.81
1.81
2.00
Basic average shares
-
224,000
231,000
236,000
242,000
Diluted average shares
-
225,000
233,000
238,000
243,000
EBITDA
-
503,000
758,000
718,000
657,000